For many pharma companies in 2020, the name of the game was COVID-19. Last year, the industry moved at breakneck speeds, forging unheard-of collaborations to deliver vaccines and therapeutics across the finish line.
More than a few of those pandemic players handed their chief executives some serious pay bumps for that work, but COVID-19 wasn't all there was to 2020's executive pay saga.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,